Economic evaluation of antiaromatase agents in the second-line treatment of metastatic breast cancer

Supportive Care in Cancer

Volumn 11, Issue 11, 2003, Pages 728-734

  Verma, Shailendra ^a   Rocchi, Angela ^b  

^a OTTAWA REGIONAL CANCER CENTRE   (Canada)

^b Axia Research   (Canada)

Author keywords

Antiaromatase agents; Breast cancer; Costs; Economic evaluation

Indexed keywords

ANASTROZOLE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; EXEMESTANE; LETROZOLE; MEGESTROL; TAMOXIFEN;

AGED; ARTICLE; BREAST CANCER; CANADA; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; ECONOMIC EVALUATION; FEMALE; HORMONE SENSITIVITY; HUMAN; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; METASTASIS; PHASE 3 CLINICAL TRIAL; POSTMENOPAUSE; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; STATISTICAL MODEL; UTILIZATION REVIEW;

AGED; ANDROSTADIENES; ANTINEOPLASTIC AGENTS; AROMATASE INHIBITORS; BREAST NEOPLASMS; CANADA; CLINICAL TRIALS, PHASE III; COST-BENEFIT ANALYSIS; ENZYME INHIBITORS; FEMALE; HUMANS; MEGESTROL; MIDDLE AGED; NITRILES; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS; SURVIVAL ANALYSIS; TRIAZOLES;

EID: 0242413719     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00520-003-0502-4     Document Type: Article

References (21)

1. Buzdar AU (2001) Endocrine therapy in the treatment of metastatic breast cancer. Semin Oncol 28:291-304
2. Buzdar A, Jonat W, Howell A, et al (1996) Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. J Clin Oncol 14:2000-2011
3. Buzdar AU, Jonat W, Howell A, et al (1998) Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma. Results of a survival update based on a combined analysis of data from two mature phase III trials. Cancer 83:1142-1152
4. Canadian Coordinating Office for Health Technology Assessment (1997) Guidelines for economic evaluation of pharmaceuticals: Canada, 2nd edn. CCOHTA, Ottawa
5. Dombernowsky P, Smith I, Falkson G, et al (1998) Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 16:453-461
6. Hillner BE, Radice D (2001) Cost-effectiveness analysis of exemestane compared with megestrol in patients with advanced breast carcinoma. Cancer 91:484-489
7. Kaufmann M, Bajetta E, Dirix LY, et al (2000) Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. J Clin Oncol 18:1399-1411
8. Laupacis A, Feeny D, Detsky AS, et al (1992) How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ 146:473-481
9. Lindgren P, Jonsson B, Redaelli A, et al. (2002) Cost-effectiveness analysis of exemestane compared with megestrol in advanced breast cancer: a model for Europe and Australia. Pharmacoeconomics 20:101-108
10. Mouridsen H, Gershanovich M, Sun Y, et al (2001) Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 19:2596-2606
11. Mouridsen H, Gershanovich M, Sun Y, et al (2003) Phase III study of letrozole versus tamoxifen as first-line therapy of advanced beast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 21:2101-2109
12. National Cancer Institute of Canada. 1995 Canadian Cancer Statistics. National Cancer Institute of Canada, Toronto
13. Nuijten M, Meester L, Waibel F, et al (1999) Cost effectiveness of letrozole in the treatment of advanced breast cancer in postmenopausal women in the UK. Pharmacoeconomics 16:379-397
14. Nuijten M, McCormick J, Waibel F, et al (2000) Economic evaluation of letrozole in the treatment of advanced breast cancer in postmenopausal women in Canada. Value Health 3:31-39
15. Ontario Ministry of Health (1994) Ontario guidelines for economic analysis of pharmaceutical products. Ontario Ministry of Health, Toronto
16. Ontario Ministry of Health (1999) Schedule of benefits for laboratory services. Ontario Ministry of Health, Toronto
17. Ontario Ministry of Health (2000) Ontario drug benefit formulary-comparative drug index, version 36D. Ontario Ministry of Health, Toronto
18. Ontario Ministry of Health (2000) Schedule of benefits-physician services. February 1998, updated April 2000. Ontario Ministry of Health, Toronto
19. Rose C, Vtoraya O, Pluzanaka A, et al (2002) Letrozole vs anastrozole second line treatment in postmenopausal women with advanced breast cancer (abstract 131). American Society of Clinical Oncology, Orlando, Florida
20. Will PB, Berthelot J-M, Houle C, et al (1993) A model for estimating the costs and burdens of breast cancer diagnosis and treatment in Canada. Health Rep 5:399-408
21. Will PB, Berthelot J, Le Petit C, et al (2000) Estimates of the lifetime costs of breast cancer treatment in Canada. Eur J Cancer 36:724-735